Kolon Life Science Inc (102940) - Total Liabilities
Based on the latest financial reports, Kolon Life Science Inc (102940) has total liabilities worth ₩295.72 Billion KRW (≈ $200.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 102940 cash flow metrics to assess how effectively this company generates cash.
Kolon Life Science Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Kolon Life Science Inc's total liabilities have evolved over time, based on quarterly financial data. Check Kolon Life Science Inc (102940) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Kolon Life Science Inc Competitors by Total Liabilities
The table below lists competitors of Kolon Life Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EVS Broadcast Equipment SA
BR:EVS
|
Belgium | €66.59 Million |
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
Germany | €77.62 Billion |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
China | CN¥420.80 Million |
|
Beijing Transtrue Technology Inc
SHE:002771
|
China | CN¥289.55 Million |
|
Beta Bionics, Inc. Common Stock
NASDAQ:BBNX
|
USA | $39.59 Million |
|
Binh Minh Plastics JSC
VN:BMP
|
Vietnam | ₫501.38 Billion |
|
Hota Industrial Mfg. Co Ltd
TW:1536
|
Taiwan | NT$13.59 Billion |
|
Calavo Growers Inc
NASDAQ:CVGW
|
USA | $83.69 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Kolon Life Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kolon Life Science Inc (102940) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kolon Life Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kolon Life Science Inc (2014–2024)
The table below shows the annual total liabilities of Kolon Life Science Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩270.23 Billion ≈ $183.13 Million |
+57.32% |
| 2023-12-31 | ₩171.76 Billion ≈ $116.40 Million |
+17.33% |
| 2022-12-31 | ₩146.39 Billion ≈ $99.21 Million |
+8.24% |
| 2021-12-31 | ₩135.25 Billion ≈ $91.66 Million |
-28.96% |
| 2020-12-31 | ₩190.38 Billion ≈ $129.02 Million |
+7.39% |
| 2019-12-31 | ₩177.27 Billion ≈ $120.14 Million |
+2.61% |
| 2018-12-31 | ₩172.76 Billion ≈ $117.08 Million |
+0.80% |
| 2017-12-31 | ₩171.38 Billion ≈ $116.14 Million |
+80.81% |
| 2016-12-31 | ₩94.78 Billion ≈ $64.23 Million |
+1.73% |
| 2015-12-31 | ₩93.17 Billion ≈ $63.14 Million |
+28.13% |
| 2014-12-31 | ₩72.72 Billion ≈ $49.28 Million |
-- |
About Kolon Life Science Inc
Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more